VPS53 Antikörper (AA 11-699)

Produktnummer ABIN7599731

Produktdetails anti-VPS53 Antikörper

Target: VPS53 (Vacuolar Protein Sorting 53 Homolog (VPS53))

Bindungsspezifität: AA 11-699

Reaktivität: Human, Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser VPS53 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunofluorescence (IF), Immunohistochemistry (IHC), Immunocytochemistry (ICC), Flow Cytometry (FACS)

Verwendungszweck: Anti-VPS53 Antibody Picoband®

Kreuzreaktivität (Details): No cross-reactivity with other proteins.

Produktmerkmale: Anti-VPS53 Antibody Picoband® (ABIN7599731). Tested in ELISA, Flow Cytometry, IF, IHC, ICC, WB applications. This antibody reacts with Human; Mouse; Rat. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.

Aufreinigung: Immunogen affinity purified.

Immunogen: E.coli-derived human VPS53 recombinant protein (Position: E11-T699).

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Western blot, 0.25-0.5 μg/mL, Human
Immunohistochemistry(Paraffin-embedded Section), 2-5 μg/mL, Human, Mouse, Rat
Immunocytochemistry/Immunofluorescence, 5 μg/mL, Human
Immunofluorescence, 5 μg/mL, Human
Flow Cytometry (Fixed), 1-3 μg/1x10⁶ cells, Human
ELISA, 0.1-0.5 μg/mL, -
1. Ben-Zeev, B., Hoffman, C., Lev, D., Watemberg, N., Malinger, G., Brand, N., Lerman-Sagie, T. Progressive cerebellocerebral atrophy: a new syndrome with microcephaly, mental retardation, and spastic quadriplegia. J. Med. Genet. 40: e96, 2003. Note: Electronic Article. 2. Brass, A. L., Dykxhoorn, D. M., Benita, Y., Yan, N., Engelman, A., Xavier, R. J., Lieberman, J., Elledge, S. J. Identification of host proteins required for HIV infection through a functional genomic screen. Science 319: 921-926, 2008. 3. Feinstein, M., Flusser, H., Lerman-Sagie, T., Ben-Zeev, B., Lev, D., Agamy, O., Cohen, I., Kadir, R., Sivan, S., Leshinsky-Silver, E., Markus, B., Birk, O. S. VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2). J. Med. Genet. 51: 303-308, 2014.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL.

Konzentration: 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: At -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freezing and thawing.

Details zu VPS53

Target: VPS53 (Vacuolar Protein Sorting 53 Homolog (VPS53))

Andere Bezeichnung: VPS53 (VPS53 Produkte)

Hintergrund:

Synonyms: Intraflagellar transport protein 88 homolog, Recessive polycystic kidney disease protein Tg737 homolog, Tetratricopeptide repeat protein 10, TPR repeat protein 10, IFT88, TG737, TTC10

Tissue Specificity: Expressed in the heart, brain, liver, lung, kidney, skeletal muscle and pancreas.

Background: Vacuolar protein sorting 53 homolog (S. cerevisiae) is a protein that in humans is encoded by the VPS53 gene. This gene encodes a protein with sequence similarity to the yeast Vps53p protein. Vps53p is involved in retrograde vesicle trafficking in late Golgi.

Molekulargewicht: 100 kDa

Gen-ID: 55275